ProfileGDS5678 / 1453716_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 31% 31% 30% 28% 30% 48% 30% 30% 31% 30% 28% 30% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7127530
GSM967853U87-EV human glioblastoma xenograft - Control 22.6977231
GSM967854U87-EV human glioblastoma xenograft - Control 32.6988331
GSM967855U87-EV human glioblastoma xenograft - Control 42.6281930
GSM967856U87-EV human glioblastoma xenograft - Control 52.5886828
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7465930
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2212948
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6665930
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6703930
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6898831
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.681230
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6157528
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6836930
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9765142